Raymond James Financial Inc. bought a new stake in shares of uniQure (NASDAQ:QURE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 110,460 shares of the biotechnology company's stock, valued at approximately $1,951,000. Raymond James Financial Inc. owned about 0.23% of uniQure at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Point72 Asset Management L.P. raised its stake in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company's stock valued at $4,816,000 after buying an additional 752,889 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of uniQure in the third quarter worth $444,000. FMR LLC increased its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company's stock valued at $1,728,000 after acquiring an additional 346,274 shares during the last quarter. Sanders Morris Harris LLC lifted its holdings in uniQure by 50.0% in the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock valued at $1,803,000 after acquiring an additional 34,034 shares during the period. Finally, Franklin Resources Inc. purchased a new position in uniQure in the third quarter worth about $7,360,000. Institutional investors own 78.83% of the company's stock.
Wall Street Analyst Weigh In
QURE has been the subject of several research reports. Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the company a "neutral" rating in a research report on Thursday, December 19th. Leerink Partners upped their target price on shares of uniQure from $26.00 to $44.00 and gave the company an "outperform" rating in a report on Wednesday, December 11th. Guggenheim reiterated a "buy" rating on shares of uniQure in a research note on Wednesday, December 11th. The Goldman Sachs Group boosted their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a "neutral" rating in a research report on Thursday, December 12th. Finally, Stifel Nicolaus raised their target price on uniQure from $12.00 to $32.00 and gave the stock a "buy" rating in a report on Monday, December 16th. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $38.80.
Check Out Our Latest Stock Report on uniQure
Insider Buying and Selling at uniQure
In other uniQure news, CFO Christian Klemt sold 10,438 shares of uniQure stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now directly owns 217,730 shares of the company's stock, valued at $2,240,441.70. This trade represents a 4.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the completion of the sale, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock worth $961,401 in the last quarter. 4.74% of the stock is owned by corporate insiders.
uniQure Price Performance
QURE traded down $0.79 during trading on Friday, hitting $8.96. 2,232,327 shares of the company traded hands, compared to its average volume of 1,676,098. The company has a market cap of $484.53 million, a PE ratio of -1.81 and a beta of 0.37. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock's 50-day simple moving average is $13.25 and its two-hundred day simple moving average is $10.91.
uniQure Company Profile
(
Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Recommended Stories
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
